Navigation Links
TechAtlas Group Releases Hepatitis C Competitive Landscape Analysis
Date:8/21/2013

BOSTON, Aug. 21, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Hepatitis C (HCV) competitive landscape map. This particular landscape highlights 25 international companies with over 60 drugs and combinations currently on the market and in development.

(Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • Winning the HCV race
  • Gilead: the one to beat
  • Debate over what is "Good Enough"
  • Other nukes
  • Leading nuke-less regimens
  • Strategic Implications of Worldwide genotype distribution
  • HCV all-oral combination timeline
  • Competitive positioning and rationale for partnerships and M&A

TechAtlas' analysts have evaluated each clinical asset and combination regimen according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, all companies are striving to win the HCV race with an all-oral, genotype-1 or pan-genotypic regimen that is convenient (QD), well-tolerated, highly effective (>90% SVR), as short as possible (12 weeks or less), has few drug-drug interactions (DDI), and works well even in patients with subclinical cirrhosis. Such a regimen could be prescribed by primary physicians with little more information than just a confirmation that the patient has HCV and possibly the viral genotype, allowing far more patients to be treated and cured than the current limited bandwidth of specialists allows, not just in the US and Europe but also in China, Egypt, and other countries were HCV is prevalent but where medical care is not as "high-touch". If multiple regimens achieve "optimal" status, or even come close, then the leaders will be at the mercy of followers willing to cut price to gain market share. But there is going to be considerable debate over what is "good enough" such that payors could push for cost-savings without being seen as compromising patient care.

The TechAtlas map graphically presents every HCV-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and a timeline of upcoming clinical milestones as well as expected earliest sales dates through 2017. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the hepatology and infectious disease community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

TechAtlas Group's current subscribers have reported that their researchers, business development executives, and senior management have used the maps to guide their business development efforts, R&D resource allocation, and competitive positioning.

Some of the 25 companies featured on the TechAtlas HCV landscape include: AbbVie, Achillion, BMS, Boehringer Ingelheim, Enanta, Gilead, GSK, Idenix, Johnson & Johnson, Merck, Novartis, Presidio, Roche, Scynexis and Vertex.  

For further information on obtaining a copy of this report through an annual subscription, please consult our website: http://www.techatlasgroup.com/order.html

About TechAtlas Group
TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA.  Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape.  As each field evolves, the maps are updated and issued to subscribers.  The TechAtlas mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.


'/>"/>
SOURCE TechAtlas Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
2. New Survey: Hispanic Teen Drug Use Significantly Higher Than Other Ethnic Groups, Substance Abuse Becoming Normalized Behavior Among Latino Youth
3. CompuGroup Medical US Announces New Laboratory Information System for the Reference Laboratory, CGM ENDEAVOR
4. Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
6. AtlantiCare Heart Heroes group donates Cardiac Science AED to Atlantic City public access defibrillation program
7. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
8. Linde Distributor Association, at twenty, is a leading buying group in the U.S.
9. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
10. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
11. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... content management, presents its enhanced Pepper Flow promotional review platform at the ... Pepper Flow’s increased insight-driven capabilities help marketers streamline the medical, legal, and ...
Breaking Medicine News(10 mins):